MapLight awarded $5.5M from Michael J. Fox Foundation for Parkinson's Research
FOR IMMEDIATE RELEASE
MapLight’s promising platform continues to garner support from leading Parkinson’s research foundation.
SAN FRANCISCO, CA, August 4, 2021 – MapLight Therapeutics announced a $5.5M million grant from The Michael J. Fox Foundation for Parkinson’s Research to develop therapeutic treatments for levodopa-induced dyskinesia (LID). A side effect of the dopamine replacement therapy used to treat Parkinson’s disease, LID involves abnormal involuntary movements that can be as debilitating as Parkinson’s disease itself.
“We are grateful for the continued support of The Michael J. Fox Foundation as we work to understand and advance treatments for Parkinson’s disease,” said Anatol Kreitzer, Ph.D., Chief Discovery Officer at MapLight. “This funding is an important step in the advancement of an exciting, first-in-class therapeutic for a disabling condition that impacts many patients.”
Dopamine treatment can provide relief from the motor symptoms of Parkinson’s disease, such as tremor, rigidity, and slow movement. However, chronic use of dopamine and advancing disease can cause an imbalance of the neural pathways that activate and inhibit movement, leading to LID. The current standard-of-care treatment for LID, amantadine, is often ineffective and can significantly impair patient cognition.
MJFF will fund MapLight’s discovery and development efforts with $5.5 million over the course of three years. The project focuses on the potential of a novel G protein-coupled receptor to limit circuit dysfunction, reducing dyskinesia without triggering other unwanted side effects.
About MapLight Therapeutics
MapLight Therapeutics is a biopharmaceutical company that discovers and develops novel therapeutics for patients with disorders of the central nervous system (CNS). MapLight’s mission is to address the critical unmet medical needs of these patients by developing innovative, targeted therapies to treat the defining clinical manifestations of their disease. The company’s circuit-based approach and proprietary discovery platform is designed to bring more effective and safer treatments to these patients by rationally developing therapies that target defective brain circuits. The company’s platform, which includes STARmap (three-dimensional spatial transcriptomics) and optogenetics, enables the identification of circuit-specific targets and validation that target modulation ameliorates disease.. Learn more at www.maplightrx.com.
Media Contact for MapLight Therapeutics